Skip to NavigationSkip to content

News

The US regulator asked for additional data from two clinical studies due to concerns over the benefit/risk profile of the medication when...
Mylan is launching the drug in a dimethyl fumarate delayed-release oral solid formulation, both in 120mg and 240mg doses.
The FDA said it needs longer term clinical trial data, and complete results from BioMarin’s two-year follow-up of its Phase 3 GENEr8-1 trial.
The deal gives Johnson & Johnson full global rights to nipocalimab, an experimental treatment for a variety of autoimmune diseases. It recently...
Smith previously became a lobbyist for Pfizer in 2005, and endorsed a company-backed report offering NHS patients easier access to private...
The London Discovery Research Centre, as the site is to be named, has a tentative opening date of 2025 and will be based opposite King’s Cross...
The deal promises “early access for every Australian”, securing 25 million doses for an undisclosed price, comfortably covering the country’s 25...
This amounts to the states seeking a collective $21.14 billion from opioid distributors including Cardinal Health, McKesson Corp and...
The government says the move has come due to the coronavirus pandemic, as they want the country to be better prepared for future pandemics.
Potentially unsafe coronavirus treatments are in the headlines this week, as President Donald Trump reportedly wants to approve Phoenix Biotechnology...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches